Integra LifeSciences (NASDAQ:IART) Releases FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of 2.410-2.490 for the period, compared to the consensus earnings per share estimate of 2.450. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its Q4 2024 guidance to 0.810-0.890 EPS.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of analyst reports. JMP Securities lowered their price objective on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Citigroup lowered their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, October 1st. Morgan Stanley raised their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Bank of America lowered their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Finally, Truist Financial cut their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $26.50.

Integra LifeSciences Price Performance

Shares of IART opened at $19.28 on Monday. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The stock has a market cap of $1.50 billion, a PE ratio of 66.48, a price-to-earnings-growth ratio of 0.64 and a beta of 1.08. The firm has a fifty day moving average price of $18.62 and a 200 day moving average price of $24.52.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.